TO THE EDITOR: Targeted agent-based therapies such as covalent Bruton tyrosine kinase inhibitors (cBTKis) and venetoclax (VEN) plus anti-CD20 monoclonal antibodies have achieved superior outcomes over chemoimmunotherapy among patients with CLL with a range of fitness and comorbidity levels, in the first-line and relapsed/refractory (RR) settings.1-7 However, data to inform the optimal sequencing of targeted agents remain limited.8-10 Continuous VEN monotherapy has demonstrated efficacy in a...
